Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C11H16N2O3S |
| Molecular Weight | 256.321 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=C(N2CCNCC2)C(=C1)S(O)(=O)=O
InChI
InChIKey=DCDFLGVJWQIRGH-UHFFFAOYSA-N
InChI=1S/C11H16N2O3S/c1-9-2-3-10(11(8-9)17(14,15)16)13-6-4-12-5-7-13/h2-3,8,12H,4-7H2,1H3,(H,14,15,16)
Caldaret is intracardiac calcium (Ca2+) handling modulator whose cardioprotective actions are presumed to be due to inhibition of the NCX exchanger and increasing the uptake of Ca2+ via the sarcoplasmic reticulum (SR). Unfortunately, Caldaret failed to demonstrate efficacy in Phase II clinical trials as an adjunct to standard therapy with primary percutaneous coronary intervention patients diagnosed as having an acute myocardial infarction
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effect of caldaret on the incidence of severe left ventricular dysfunction in patients with ST-elevation myocardial infarction undergoing primary coronary intervention. | 2009-01-01 |
|
| Caldaret, an intracellular Ca2+ handling modulator, limits infarct size of reperfused canine heart. | 2007-02 |
|
| Results of the first clinical study of adjunctive CAldaret (MCC-135) in patients undergoing primary percutaneous coronary intervention for ST-Elevation Myocardial Infarction: the randomized multicentre CASTEMI study. | 2006-11 |
|
| A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design. | 2004-06 |
|
| Breast-feeding may reduce later blood pressure. | 2004-03-16 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C333
Created by
admin on Mon Mar 31 18:33:39 GMT 2025 , Edited by admin on Mon Mar 31 18:33:39 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
300000036945
Created by
admin on Mon Mar 31 18:33:39 GMT 2025 , Edited by admin on Mon Mar 31 18:33:39 GMT 2025
|
PRIMARY | |||
|
9L3Y3IJ2HI
Created by
admin on Mon Mar 31 18:33:39 GMT 2025 , Edited by admin on Mon Mar 31 18:33:39 GMT 2025
|
PRIMARY | |||
|
DB06231
Created by
admin on Mon Mar 31 18:33:39 GMT 2025 , Edited by admin on Mon Mar 31 18:33:39 GMT 2025
|
PRIMARY | |||
|
DTXSID80158376
Created by
admin on Mon Mar 31 18:33:39 GMT 2025 , Edited by admin on Mon Mar 31 18:33:39 GMT 2025
|
PRIMARY | |||
|
C77830
Created by
admin on Mon Mar 31 18:33:39 GMT 2025 , Edited by admin on Mon Mar 31 18:33:39 GMT 2025
|
PRIMARY | |||
|
CHEMBL2106572
Created by
admin on Mon Mar 31 18:33:39 GMT 2025 , Edited by admin on Mon Mar 31 18:33:39 GMT 2025
|
PRIMARY | |||
|
8113
Created by
admin on Mon Mar 31 18:33:39 GMT 2025 , Edited by admin on Mon Mar 31 18:33:39 GMT 2025
|
PRIMARY | |||
|
C487217
Created by
admin on Mon Mar 31 18:33:39 GMT 2025 , Edited by admin on Mon Mar 31 18:33:39 GMT 2025
|
PRIMARY | |||
|
6433076
Created by
admin on Mon Mar 31 18:33:39 GMT 2025 , Edited by admin on Mon Mar 31 18:33:39 GMT 2025
|
PRIMARY | |||
|
133804-44-1
Created by
admin on Mon Mar 31 18:33:39 GMT 2025 , Edited by admin on Mon Mar 31 18:33:39 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
